Eli Lilly is on track for pivotal approvals in 2026, including its obesity pill and the oral GLP-1 drug Foundayo, projected to generate significant revenue. The company's recent Phase 3 trial success for Jaypirca showcases its commitment to enhancing treatment options in oncology, while its dominant GLP-1 drugs, Mounjaro and Zepbound, continue to drive substantial sales growth. With an optimistic outlook supported by a robust pipeline and improving credit quality, Eli Lilly is solidifying its competitive position in the healthcare market.
“Eli Liy has a pill under development, which they are hoping they will gain approval sometime in 2026, sometime in the middle of 2026.”
“ELI LILLY REPORTS THAT SAFETY RATINGS ARE CONSISTENT, WITH SIMILAR RATES OF ADVERSE EVENTS ACROSS DIFFERENT STUDY GROUPS.”
“$LLY - Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL”
“$LLY announces positive topline results from Phase 3 BRUIN CLL-322 trial of Jaypirca in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).”
“礼来是 $LLY 是医药平衡组合风险，风险回报比也很不错，去年到现在，可继续关注新的减肥药上市下一步。”
“去年到现在，可继续关注新的减肥药上市下一步。”
“which really undercuts the price for the higher doses of its rival, Eli Lilly, and the Zepbound offering by about 100 bucks.”
“right now we have Lilly on positive outlook. I think if you look at the growth story here for Lilly it's it's it's really just leading the entire industry.”
“Whereas Lilly is really improving. You know right now we're just focused on that improving credit quality at Lilly.”
“You think about Eli Lilly's own obesity pill. Are you still on track potentially for that March approval? Yes, we are on track. We submitted for regulatory approval, actually, and we are expecting that to take place as early as Q2 this year.”
“And we have to talk a little bit about pricing too, because in November you struck a deal with the Trump administration to lower prices when it comes to weight loss drugs.”
“Actually, at this conference last year, Eli Lilly announced a deal with cancer biotech Scorpion.”
